Warner Bros. will pull out of the South Korean market due to years of disappointing performances, and will merely wrap up projects that are in post-production or production.
An official from Warner Bros Korea, the South Korean production and distribution unit of the US film studio, added that they have stopped investing in Korean films.
It is now handling three titles, including “Josee,” a remake of a 2003 Japanese drama, which would be released in November.
Warner Bros. Korea made a box office hit in its 2016 debut with its first Korean project, “The Age of Shadows,” a period drama by Kim Jee-woon starring actor Song Kang-ho.
The Age of Shadows raked in over $57 million and was South Korea’s entry for the foreign-language Oscar.
But subsequent films like “A Single Rider” in 2017 and “Illang: The Wolf Brigade” in 2018 were flops.
The local movie-production market is dominated by four giant investor-distributors: CJ, Lotte, NEW, and Showbox.


Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 



